CYBERDYNE Inc.

CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides Cybernics Treatment, a treatment that uses HAL to enhance/regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; HAL FIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT for enhancement of physical functions. In addition, the company is involved in the provision of rescue supports in disaster sites, and heavy labor supports for factories and plants; and entertainment business. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.

CYBERDYNE Inc. trades as CYBQF on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $3.87B of revenue and $153.96M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

CYBERDYNE Inc. can be compared against peers such as BICO Group AB (publ), BrainsWay Ltd., CareRx Corporation, BICO Group AB (publ), JW (Cayman) Therapeutics Co. Ltd, Medical Facilities Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $248.85M, beta of 0.85, and return on equity of +0.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CYBQF currently shows total debt of $771.83M and beta of 0.85. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cyberdyne.jp

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.